Following changes were made: Combined inclusion criteria 4 and 5 in to one sentence; changed the high risk of tumor lysis syndrome (TLS) definition of AL subjects from “A. white blood cell (WBC) greater than or equal to (>=) 10.0*10^9/L, or B. WBC less than (<)10.0* 10^9/L with C. lactate dehydrogenase (LDH) >=2* upper limit of normal (ULN)” to “A. WBC >=100.0* 10^9/L, or B. WBC <100.0* 10^9/L with LDH >=28 ULN”; deleted “and with life expectancy of >3 months” in the last inclusion criteria; changed the inclusion criteria 4 from “newly diagnosed NHL or AL; or during the intermission of chemotherapy at screening with hyperuricemia: blood uric acid >8 mg/dL (473 micromole per liter [mcmol/L]).” to “newly diagnosed NHL or AL who was at the initiation of or during the first cycle of chemotherapy, baseline blood uric acid >8 mg/dL (473 mcmol/L) at screening”; changed inclusion criteria 5 from “If newly diagnosed NHL subject with blood uric acid <=8 mg/dL at screening, the subject might diagnosed with Stage III or IV NHL with high tumor burden defined, with one or more of following below” to “If newly diagnosed NHL subject with blood uric acid <=8 mg/dL at screening, the subject might diagnosed with stage III or IV NHL with high tumor burden which would high risk of TLS defined; added “lactate dehydrogenase”, full name of LDH, before LDH in inclusion criteria 5-C; changed the high risk of TLS definition of AL subject from “A. WBC >=10.0* 10^9/L, or B. WBC <10.0* 10^9/L with LDH >=2* ULN” to “A. WBC >=100.0* 10^9/L, or B. WBC <100.0* 10^9/L with LDH >=28 ULN”; changed the sponsor from “Shanghai Branch of Sanofi (China) Investment Co., Ltd.” to “Sanofi (Beijing) pharmaceutical co., LTD”; changed the address from “F19, Tower 3, Kerry Center, 1228 Middle Yan’an Road, Shanghai, China” to “Haihang Industrial building, No. 108 Jian Guo Road, Chaoyang District, Beijing 100022, China”; delete “Tel: 021-22266666 Fax: 021-62880569”.

Following changes were made: Changed the endpoints from “For subject who aged <10 years old, written informed consent form (ICF) of subject/legal guardian (as appropriate) was required. For subject who aged 10-18 (inclusive), both written ICF of minor assent form and subject/legal guardian are required.” to For subject who aged <8 years old, written ICF of subject/legal guardian (as appropriate) is required. For subject who aged 8-18 (inclusive), both written ICF of minor assent interruptions form and subject/legal guardian are required; Added “Previous glucose-6-phosphate dehydrogenase testing result was acceptable.

Following changes were made: Changed the endpoint(s) from “In those subject whose baseline plasma uric acid levels are <=8 mg/dL but with a high risk of TLS, the proportion of subject who can maintain the normal uric acid levels throughout the study (from first administration to the end of follow-up: 14 days after the first administration)“ to “In those subject whose Baseline plasma uric acid levels are <=8 mg/dL but with a high risk of TLS, the proportion of subject who can maintain the normal uric acid levels throughout the study (from first administration to the end of follow-up: 7 days after the first administration)“; Changed the procedures of collecting and measuring the uric acid blood sample from “Draw 1 milliliter (mL) whole blood for each collection tube” to “Draw 4 mL whole blood for each collection tube”; Added “This was a post market commitment study and the design of this protocol was served the same commitment purpose of study protocol number “RASBUL06535”, which was cited by national master processing agreement in the imported drug license NO.S20180024”in introduction and rational.